Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

ConferencepositiveDarlifarnibCabozantinibPositive

AI Analysis

Summary

Kura Oncology reported durable clinical activity for darlifarnib plus cabozantinib in cabozantinib-naïve clear cell renal cell carcinoma patients, with response rates up to 50% and median PFS of 13 months presented at KCRS 2026.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Response rates up to 50% across evaluated dose levels and median PFS of 13 months in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients

Importance:6/10

Sentiment:

0.70

oncologyrenal cell carcinomacombination therapyclinical dataKCRS 2026

Related Companies

$DFPH $ALMDT.PA

Read the original article

Published by GlobeNewswire Pharma on July 27, 2026 10:32 AM

Read Original